ITP (immune thrombocytopenia) is an autoimmune disorder where the body attacks its own blood platelets. This leads to a decrease in the number of platelets and consequently can cause a number of ...

Agios Pharmaceuticals AGIO has inked an agreement with Oscotec, a South Korea-based biotech, in-licensing exclusive global ...

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy. I think the major challenges in ITP are several. One, and I think the [rilzabrutinib] ...

About half of people with ITP say the condition affects their emotional and psychological health, and about one-third of them say it causes them to feel self-conscious about their appearance. Moreover ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...

SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP). In the LUNA ...

Recently published Immune Thrombocytopenia Market Insights report includes a comprehensive understanding of current treatment ...

The prize is an oral spleen tyrosine kinase (SYK) inhibitor, called cevidoplenib, which has been developed by Korea’s Oscotec ...

BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...

The immune thrombocytopenia market is experiencing steady growth driven by increasing disease awareness and improved diagnosis rates. Advancements in targeted therapies, including thrombopoietin ...